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En bloc radical vulvectomy with bilateral inguinofemoral lymphadenectomy has now been replaced by radical wide excision and
selective inguinal lymphadenectomy based on the stage and location of invasive vulvar cancer. Early stage lateral cancers can be
eﬀectively treated by radical wide excision and ipsilateral superﬁcial inguinal lymphadenectomy. Lymph node mapping using
perilesional injection of radiocolloid and blue dye may identify sentinel lymph nodes which can be removed, thereby avoiding the
morbidity of full inguinal lymphadenectomy in selected patients with early stage disease.
1.Introduction
Although squamous cell carcinoma of the vulva is not com-
mon, it is occurring with increasing frequency in younger
women, particularly in those exposed to human papilloma
virus (HPV). With eﬀorts at education, many patients are
presenting with early stage disease which is amenable to
surgery. This year, there will be approximately 3500 new
c a s e so fv u l v a rc a n c e ri nt h eU n i t e dS t a t e s ,r e p r e s e n t i n g5 %
of all gynecologic cancers [1]. The surgical management of
this disease has evolved from en bloc resection of the entire
vulvawithbilateralsuperﬁcialanddeepinguinofemorallym-
phadenectomy to a more conservative approach involving
radical wide excision of the primary lesion and speciﬁc
types of inguinal lymphadenectomy based on the stage and
anatomic location of disease.
2.AnatomicPathwaysof Spreadand Staging
The lymphatic drainage of the vulva has been studied
extensively and described in numerous publications [2, 3].
Generally, lateralizing lesions (>1cm beyond the midline)
drain to the ipsilateral superﬁcial inguinal lymph nodes,
whereas midline lesions can drain to either side (Figure 1).
It isextremely rare for lateralizing vulvar cancers to spread to
thecontralateralinguinal lymph nodesifthere isno evidence
of ipsilateral lymph node metastases. Likewise, it is unusual
for the deep inguinal nodes (below the cribriform fascia) to
beinvolvedin theabsenceofsuperﬁcial inguinal lymph node
spread. The current International Federation of Gynecology
a n dOb s t e t r i c sS t a gi n gS y s t e mf o rv u l v a rc a n c e ri sn o wb a s e d
on surgical ﬁndings as illustrated in Table 1 and reﬂects the
extent and location of inguinal lymph node metastases.
3.Surgeryofthe PrimaryVulvarLesion
The Basset-Way operation which was the standard of care
in the operative management of patients with vulvar cancer
included the en bloc resection of the primary lesion and
s u r r o u n d i n gv u l v a rs k i na sw e l la st h es k i no v e rb o t hg r o i n s
(Figure 2(a))[ 4]. Although this procedure was curative in
the majority of cases, the wound defect was signiﬁcant
and incisional breakdown and lymphedema of both lower
extremities were common. Currently, the surgical treatment
ofvulvar cancerinvolvesradical wide excision oftheprimary
lesion and inguinal lymphadenectomy through separate
groin incisions (Figure 2(b))[ 5]. Heaps and colleagues [6]
reported that local control of vulvar cancers could be
achieved in 100% of cases provided that a 1cm margin of
normal skin was included in the surgical specimen. These2 International Journal of Surgical Oncology
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Figure 1: Lateral vulvar lesions >1cm from the midline (a) spread initially to the ipsilateral superﬁcial inguinal lymph nodes, whereas
midline lesions can spread to both groins (b).
(a) (b)
Figure 2: The Bassett-Way operation includes en bloc radical resection of the primary lesionand surrounding vulvar skinas well as the skin
over both groins (a). Radical wide excision of the vulvar cancer includes a margin of at least 1cm of normal skin around the entire lesion.
Inguinal lymphadenectomy is performed through separate groin incisions (b).
observations were conﬁrmed by De Hullu and coworkers [7]
who reported that there was no local recurrence of T1 or
T2 vulvar cancers when a margin of at least 8mm normal
skinwasexcisedwiththeprimarylesion.Incontrast,patients
with a margin of <8mm had a local recurrence rate of 22%.
At present, it is recommended that a margin of at least 1cm
of normal skin around the circumference of the primary
vulvar lesion be included in the surgical specimen and that
the underlying subcutaneous tissue be removed to the level
of the perineal fascia. Inguinal lymphadenectomy is then
performed through separate incisions.
4.SentinelLymphadenectomy
Sentinel lymph node excision is now being recommended in
selected patients with early stage squamous cell carcinoma
as a means to avoid the operative morbidity associated with
inguinofemoral lymphadenectomy [8–10]. It is estimated
that only 25–30% of patients with early stage vulvar cancer
have lymph node metastases, and complete inguinofemoral
lymphadenectomy is associated with postoperative wound
complications and lower extremity edema in 30–40% of
patients [11]. Sentinel lymph node mapping using radio-
labelled ultraﬁltered sulfur colloid was initially reported as
a method to identify regional lymph node metastases in
breast cancer [12, 13] and cutaneous melanoma [4]a n dh a s
nowbeenevaluatedin patientswithearly stagevulvar cancer.
Speciﬁcally, 1-2mCi of radiocolloid is injected intradermally
around the lesion (Figure 3), and a hand held gamma
detection device is used to identify the sentinel lymph
node(s). Recently, lymphoscintigraphy has been combined
with intraoperative perilesional injection of isosulfan blue
as a method to identify sentinel nodes in the inguinal area.
Localization of the sentinel node(s) is usually apparent 5–15
minutesafterinjectionofbluedyeand30minutesafterinjec-
tion of radiocolloid. Selman and colleagues [14] performed
a systematic review of the accuracy of sentinel lymph node
detection in identifying inguinal lymph node metastases in
vulvar cancer and reported that the combination of 99mTc
radiocolloid and isosulfan blue dye successfully detected
sentinel lymph nodes in 97% of cases. It also had a negative
predictive value (NPV) of 99.1%. Further analysis has
indicatedthatsentinel lymphnodemapping ismostaccurate
in patients with early stage lateral vulvar cancers [15].
Apersisting concernaboutsentinellymphnodemapping
in vulvar cancer is the frequency of groin recurrences in
patients with negative sentinel lymph nodes. In a multi-
institutionalobservational study,Van DerZeeandcoworkersInternational Journal of Surgical Oncology 3
Table 1: FIGO staging of invasive cancer of the vulva.
Stage I Tumor conﬁned to the vulva
IA
Lesions ≤2cm in size conﬁned to the vulva or
perineum and with stromal invasion ≤1.0mm∗,
no nodal metastasis
IB
Lesions >2cm in size conﬁned to the vulva or
perineum with stromal invasion greater than 1.0mm∗,
no nodal metastasis
Stage II
Tumor of any size with extension to adjacent perineal
structures (1/3 lower urethra, 1/3 lower vagina, anus),
no nodal metastasis
Stage III
Tumor ofany size with or without extension to adjacent
perineal structures (1/3 lower urethra, 1/3 lower vagina,
anus) with positive inguinofemorallymph nodes
IIIA With 1 lymph node metastasis (≥5mm),
IIIB (i) With 2 or more lymph node metastases (≥5mm),
(ii) 3 or more lymph node metastases (<5mm)
IIIC With positive nodes with extracapsular spread
Stage IV Tumor invades other regional (2/3 upper urethra, 2/3
upper vagina) or distant structures
IVA
Tumor invades any of the following:
(i) Upper urethra and/or vaginal mucosa, bladder
mucosa, rectal mucosa, or ﬁxed to pelvic bone,
(ii) Fixed or ulcerated inguinofemoral lymph nodes
IVB Any distant metastasis including pelvic lymph nodes
∗The depthof invasionis deﬁnedasthe measurementofthe tumorfrom the
epithelial-stromaljunctionofthe adjacent mostsuperﬁcialdermal papillato
the deepest point of invasion.
Figure 3: Sentinel lymph node mapping. Sentinel lymph nodes
are localized by perilesional injection of 99mTc radiocolloid and
isosulfanblue dye.
[10] performed the sentinel node procedure in 623 groins of
403 assessable patients. Two hundred ﬁfty-nine patients with
unifocal vulvar cancers <4cm diameter and negative sentinel
nodeswerefollowed withoutadditionaltherapyforamedian
of 35 months. Six groin recurrences (2.3%) were observed,
and the 3-year survival of these patients was 97%. Impor-
tantly, both short-term morbidity and long-term morbidity
of patients having sentinel node excision were signiﬁcantly
reduced when compared to that of women undergoing
complete inguinofemoral lymphadenectomy. These authors
concluded that sentinel node dissection, performed by a
quality-controlled multidisciplinary team, should be oﬀered
to selected patients with early stage vulvar cancer as a
means to avoid the postoperative morbidity associated with
inguinofemoral lymphadenectomy.
There is a deﬁnite learning curve in the performance
and interpretation of lymph node mapping, and it is
recommended that a multidisciplinary group within each
institution perform sentinel node mapping in at least 10–
20 cases before it becomes an accepted procedure [10, 16].
If sentinel lymph nodes cannot be identiﬁed by mapping or
ifthereisuncertaintyconcerninginterpretationofﬁndings, a
superﬁcial inguinal lymphadenectomy should be performed.
Patients with a positive sentinel node should undergo a
full inguinofemoral lymphadenectomy followed by postop-
erative radiation therapy to the involved groin and pelvis.
However, if the sentinel lymph nodes identiﬁed by mapping
are histologically negative after review by an experienced
multidisciplinary team, no further treatment is indicated.
It should be emphasized that optimal candidates for sen-
tinellymphnodemappingarepatientswho havelateralT1 or
T2 unifocal vulvar cancers <4cm diameter with nonpalpable
groin nodes [10]. This procedure is less accurate in patients
with midline vulvar lesions or those with advanced stage
disease and clinically palpable inguinal nodes [17].
5.SuperﬁcialInguinal Lymphadenectomy
Many surgeons concerned about the accuracy of sentinel
lymph mapping have elected to perform superﬁcial inguinal
lymphadenectomy as the treatment of choice in patients
with early stage vulvar cancer, believing that the superﬁcial
inguinal nodes are themselves “sentinel nodes.” Speciﬁcally,
all inguinal lymph nodes above the cribriform fascia are
removed en bloc (Figure 4). Approximately 8–10 lymph
nodes are excised, and the saphenous vein is preserved
in order to decrease the frequency of postoperative lower
extremity lymphedema [18, 19]. Berman and coworkers
[20] reported the outcomes of 50 patients with T1 vulvar
cancers <1cm diameter with stromal invasion >5mmwho
underwent radical wide excision and superﬁcial inguinal
lymphadenectomy. Women with positive superﬁcial inguinal
nodes underwent deep inguinal lymphadenectomy and
radiation, whereas patients with negative superﬁcial inguinal
nodes received no further treatment. There were no isolated
groin recurrences noted during a follow-up period of 36
months. Importantly, only 1 patient died of recurrent
cancer, and wound complications were observed in only
12% of patients. These authors concluded that radical wide
excision of the primary lesion and superﬁcial inguinal
lymphadenectomy was the treatment of choice for most
women with early stage vulvar cancer and no evidence of
enlarged inguinal lymph nodes on clinical examination. A
persisting concern of this approach has been a signiﬁcant
but low incidence of groin recurrence in patients with
negative superﬁcial inguinal lymph nodes at the time of4 International Journal of Surgical Oncology
Figure 4: Radical wide excision and ipsilateral superﬁcial inguinal
lymphadenectomy is performed for lateral T1 or T2 vulvar cancers.
All lymph nodes above the cribriform fascia are removed and the
saphenous vein is preserved.
lymphadenectomy. Two investigators have reported a 4–
7% incidence of subsequent ipsilateral groin failure after
negative primary superﬁcial groin dissection [21, 22]. This
is worrisome since the majority of patients with groin
recurrence died of their disease. However, these studies were
retrospective and in one series [21] the anatomic location
of the primary vulvar lesion was not reported. In the most
recent investigation [22], vulvar cancers that recurred in the
groin after negative superﬁcial inguinal lymphadenectomy
were central periclitoral lesions and the number of lymph
nodes removed was small (∼3 per groin). Therefore, these
authors recommend superﬁcial inguinal lymphadenectomy
as the initial surgical approach in patients with lateral Stage I
or Stage II vulvar cancers provided that an adequate number
ofsuperﬁcial inguinal lymphnodes(8–10)are removed[22].
Currently, superﬁcial inguinal lymphadenectomy should be
considered only in patients with lateral T1 and T2 vulvar
cancers having >1mm stromal invasion and no clinical
evidence of enlarged groin nodes.
6.Deep Inguinal Lymphadenectomy
Anatomic studies have indicated that some superﬁcial
inguinal nodes may be located within the interstices of the
cribriform fascia and could be missed by purely superﬁcial
inguinal lymphadenectomy [23]. Therefore, some surgeons
choose to perform deep inguinal lymphadenectomy rou-
tinely at the time of superﬁcial inguinal lymphadenectomy.
The deep femoral lymph nodes are always located within
the opening of the fossa ovalis medial to the femoral vein,
and no lymph nodes are distal to the lower margin of the
fossa ovalis or lateral to the femoral vein (Figure 5). For this
reason, incision of the deep fascia of the adductor canal and
dissection of the femoral vessels, sometimes performed as
part of this procedure, are unnecessary. This is important
since deep fascial incision and stripping of the femoral
vessels is associated with postoperative wound breakdown,
lymphocyst formation, and lower extremity edema in up to
40% of cases [11, 24].
Figure 5: Radical wide excision and bilateral inguinofemoral
lymphadenectomy is performed for midline vulvar cancers. This
illustration depicts the right superﬁcial inguinal lymph nodes and
the left deep femoral lymph nodes which are seen along the medial
aspect of the fossa ovalis.
At one time, patients with positive superﬁcial or deep
inguinal nodes were treated by pelvic lymphadenectomy.
However, a prospective trial conducted by the Gynecologic
Oncology Group showed that patients with inguinal lymph
node metastasis at the time of groin dissection who were
treated by postoperative inguinal and pelvic radiation had
a signiﬁcant survival advantage when compared to similar
patients treated by pelvic lymphadenectomy [25]. Patients in
the radiation therapy arm received 45–50Gy to the involved
groin and pelvis, whereas patients randomized to pelvic
lymphadenectomy underwent a standard extraperitoneal
excision of the obturator, external iliac, internal iliac, and
common iliac lymph nodes. This trial showed a statistically
signiﬁcant survival advantage to patients in the radiation
therapy arm (68% versus 54% observed survival) on interim
analysis [26]. Therefore, most vulvar cancer patients with
positive superﬁcial or deep inguinal lymph node metas-
tases at the time of inguinal lymphadenectomy are treated




Anatomic studies have conﬁrmed that eﬀerent lymphatics
from the lateral vulva drain initially to the ipsilateral
superﬁcial inguinal lymph nodes [2, 27]. Likewise, lateral
vulvar cancers (>1cm beyond the midline) do not spread
to the contralateral inguinal lymph nodes without ﬁrst
involving the ipsilateral inguinal nodes [27, 28]. These
anatomic observations have led toc l i n i c a lt r i a l se v a l u a t i n g
the eﬃcacy of radical wide excision and ipsilateral inguinal
lymphadenectomy in the treatment of lateral vulvar cancers.
DeSimone and coworkers [29], for example, treated 122
patients with lateral T1 or T2 vulvar cancers by radical
vulvectomy (N = 60) or radical wide excision (N = 62)
andbilateralinguinallymphadenectomy.Twenty-six patients
(21%) had ipsilateral inguinal lymph node metastases, butInternational Journal of Surgical Oncology 5
there were no cases of spread to the contralateral inguinal
lymph nodes. Patients with positive inguinal nodes were
treated by postoperative radiation therapy to the involved
groin and pelvis. All patients in the study were followed
periodically by clinical examinations 10–195 months (mean
59 months) after treatment. Eighteen patients (15%) devel-
oped recurrent vulvar cancer—13 to the ipsilateral vulvar
skin, 2 to the ipsilateral groin, and 3 to the lung. There
were no recurrences to the contralateral vulvar skin or groin.
Likewise, there was no diﬀerence in the local recurrence rate
of patients treated by radical vulvectomy versus those treated
by radical wide excision. The 5-year disease-free survival was
98%forpatientswithT1 lesionsand93%forpatientswithT2
lesions. These authors concluded that women with lateral T1
and T2 vulvar cancers could be treated eﬀectively by radical
wide excision and ipsilateral inguinal lymphadenectomy.
There is still some controversy concerning the per-
formance of routine contralateral inguinofemoral lym-
phadenectomy in patients with lateral vulvar cancers and
positive ipsilateral inguinal nodes. Isolated reports have
indicated that contralateral inguinal lymph node metastases
can occur in these patients. However, the frequency of
contralateral spread in these patients is extremely low, and
the risk of contralateral inguinal lymphadenectomy may
outweigh its beneﬁts, particularly if only a small number of
ipsilateral nodes are positive.
All vulvar cancers located within 1cm of midline struc-
tures (clitoris, vagina, or anus) have the potential to spread
tobothgroins, and shouldbetreatedbyradical wideexcision
and bilateral inguinofemoral lymphadenectomy.
8.Summary
The Bassett-Way operation, which emphasized en bloc
resection of the vulva and both groins, has been replaced
by radical wide excision and selective inguinal lymphadenec-
tomy through separate groin incisions. The speciﬁc type of
inguinal lymphadenectomy indicated depends on the stage
and location of each cancer. Early stage lateral vulvar cancers
can be treated safely by radical wide excision and ipsilat-
eral superﬁcial inguinal lymphadenectomy, whereas central
vulvar cancers require bilateral inguinal lymphadenectomy.
Deep inguinal lymphadenectomy, which involves surgical
removal of the deep femoral nodes, is indicated in patients
with centrally located early stage vulvar cancers, advanced
stage vulvar cancers, and in patients with positive superﬁcial
inguinal lymph nodes. The deep femoral lymph nodes
are always located medial to the femoral vein and can
be removed without incising the deep fascia or dissecting
the femoral vessels. Sentinel lymph node mapping should
be oﬀered to select patients with early stage lateral vulvar
cancers as a means to avoid the postoperative morbidity
associated with full inguinofemoral lymphadenectomy.
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